Genome Sequence Variability Predicts Drug Precautions and Withdrawals from the Market
Loading...
Authors
Lee, Kye H.
Baik, Su Y.
Lee, Soo Y.
Park, Chanjae H.
Park, Paul J.
Kim, Ju H.
Issue Date
2016
Type
Article
Language
Keywords
Alternative Title
Abstract
Despite substantial premarket efforts, a significant portion of approved drugs has been withdrawn from the market for safety reasons. The deleterious impact of nonsynonymous substitutions predicted by the SIFT algorithm on structure and function of drug-related proteins was evaluated for 2504 personal genomes. Both withdrawn (n = 154) and precautionary (Beers criteria (n = 90), and US FDA pharmacogenomic biomarkers (n = 96)) drugs showed significantly lower genomic deleteriousness scores (P < 0.001) compared to others (n = 752). Furthermore, the rates of drug withdrawals and precautions correlated significantly with the deleteriousness scores of the drugs (P < 0.01) this trend was confirmed for all drugs included in the withdrawal and precaution lists by the United Nations, European Medicines Agency, DrugBank, Beers criteria, and US FDA. Our findings suggest that the person-to-person genome sequence variability is a strong independent predictor of drug withdrawals and precautions. We propose novel measures of drug safety based on personal genome sequence analysis.
Description
Citation
Lee, K. H., Baik, S. Y., Lee, S. Y., Park, C. H., Park, P. J., & Kim, J. H. (2016). Genome Sequence Variability Predicts Drug Precautions and Withdrawals from the Market. PLOS ONE, 11(9), e0162135. doi:10.1371/journal.pone.0162135
Publisher
License
Creative Commons Attribution 4.0 International
Journal
Volume
Issue
PubMed ID
ISSN
1932-6203